Amaliyotchi shifokorlarga
SYuYe/HF (surunkali yurak yetishmovchiligi/heart failure) va
SBK/CKD (surunkali buyrak kasalligi/Chronic kidney disease) bor patsientlar, davolash uchun murakkab kategoriya hisoblanadi. Asosiy sabablar, bu
asoratlar xavfini yuqoriligi, hamroh kasalliklar (
multimorbidlik) va dorilar soni ko’pligi (
polypharmacy). Bu bemorlarni sinchkovlik bilan baholash va
SYuYe/HF davolash bo’yicha tavsiyalarga amal qilish muhimdir: HF davolashning to'rtta ustuni (beta-blokatorlar, RAASi [ACEi, ARB, ARNI], MRA va SGLT2i), diuretiklar, temir preparatlari va ko'rsatma asosida device therapiya (tibbiy jixozlar implantatsiyasi) hamda buyrak funktsiyasi va giperkalemiyani qat’iy nazorati. Buyrak funktsiyasining yomonlashuvi va giperkalemiya ehtimolini kamaytirish uchun bemorlarni “kasallik kuni” qoidalariga o'rgatish kerak (patsient o’zida keskin suvsizlanish belgilari yuzaga kelganida, qaysi dorilarni vaqticha to’xtashi kerakligini bilishi shart!).
ACEi: angiotensin converting enzyme inhibitor;
ARB: aldosterone receptor blocker;
ARNI: angiotensin receptor-neprilysin inhibitor;
SGLT2i: sodium-glucose cotransporter-2 inhibitor;
MRA: mineralocorticoid receptor antagonist;
IV: intravenous;
ICD: implantable cardioverter defibrillator;
CRT: cardiac resynchronisation therapy;
HF: heart failure;
HFrEF: heart failure with reduced ejection fraction;
HFmrEF: heart failure with middly reduced ejection fraction;
HFpEF: heart failure with preserved ejection fraction;
doi.org/10.31083/j.rcm2504144